FAQs about Ponvory

Ponvory was approved by the U.S. Food and Drug Administration in March 2021 for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis.

Animal studies suggest that Ponvory may cause harm to a developing fetus. People with the potential to become pregnant should use contraception methods while on Ponvory and for one week after stopping treatment.

No interactions between Ponvory and alcohol have been reported. But patients should discuss with their healthcare provider whether it is safe to drink alcohol while on Ponvory, since alcohol can sometimes interfere with disease symptoms and medications.

Some patients may begin seeing results as early as six months after beginning treatment. In a Phase 2 trial involving more than 450 people with relapsing-remitting multiple sclerosis, those who received the recommended dose of Ponvory had a significant reduction in new inflammatory lesions after six months, compared with patients receiving a placebo. However, multiple sclerosis manifests very differently among patients, and people’s responses to treatment also vary. Patients should talk with their healthcare team to understand how the medication might help in their specific case.

Weight gain has not been reported in clinical trials as a side effect associated with Ponvory. Hair loss (alopecia), however, was reported by a small percentage of patients in the OPTIMUM Phase 3 trial. Patients are advised to discuss with their healthcare provider if they experience these problems.

Related Articles